Skip to main content
. 2009 May 4;27(18):3036–3043. doi: 10.1200/JCO.2008.19.8903

Fig 3.

Fig 3.

Time to progression by prior therapy: (A) treatment-naive patients and (B) patients with relapsed/refractory disease. Mitumprotimut-T:placebo hazard ratio (HR) = 1.196;P = .258 for treatment-naive patients. Mitumprotimut-T:placebo HR = 2.265, P = .004 for patients with relapsed/refractory disease. GM-CSF, granulocyte-macrophage colony-stimulating factor.